Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

340B Dispute Resolution Rule Likely Violated Proper Regulatory Procedures – Court

Executive Summary

Ruling halts the 340B rule, and may have relevance in a suit brought by PBMs challenging the ‘rebate rule,’ which was issued in final form after HHS had suspended action on the reg.

You may also be interested in...



340B Fight Escalates As Biden Administration Seeks Refunds From Manufacturers, Threatens Them With Fines

Lilly, AstraZeneca, Novartis, Sanofi, Novo Nordisk and United Therapeutics ordered by HRSA to resume discounts to 340B contract pharmacies and refund past 'overcharges.'

Medicare Part D Rebate Rule Delayed Until 2023 As PBMs Notch Legal Win

HHS initially postponed only those provisions of the final regulation that were scheduled to go into effect 29 January, but Biden Administration now faces April deadline from court to determine how to proceed with the rest of the rule.

340B Dispute Resolution Process On Ice As Feuds Between Pharma, Providers, HHS Heat Up

Biden Administration’s regulatory freeze suspends HHS action to appoint an administrative dispute resolution board for the 340B program. Good news for manufacturers?

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS144009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel